Float Short %

4.34

Margin Of Safety %

Put/Call OI Ratio

0.04

EPS Next Q Diff

0.04

EPS Last/This Y

0.21

EPS This/Next Y

0.34

Price

4.11

Target Price

Analyst Recom

Performance Q

2.5

Upside

-1,337.8%

Beta

1.91

Ticker: ADCT

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-01-23	ADCT	3.61	0.05	7.00	1231
2026-01-26	ADCT	3.62	0.06	0.00	1238
2026-01-27	ADCT	3.58	0.06	0.00	1238
2026-01-28	ADCT	3.55	0.06	0.17	1238
2026-01-29	ADCT	3.77	0.06	0.00	1231
2026-01-30	ADCT	3.62	0.06	0.00	1255
2026-02-02	ADCT	3.89	0.06	0.00	1241
2026-02-03	ADCT	3.9	0.06	0.00	1286
2026-02-04	ADCT	4.1	0.06	0.00	1291
2026-02-05	ADCT	3.91	0.06	0.00	1303
2026-02-06	ADCT	4	0.06	0.00	1329
2026-02-09	ADCT	3.98	0.06	0.00	1328
2026-02-10	ADCT	3.91	0.06	0.03	1335
2026-02-11	ADCT	3.92	0.05	0.00	1483
2026-02-12	ADCT	4.01	0.05	0.00	1621
2026-02-13	ADCT	3.99	0.05	0.03	1624
2026-02-17	ADCT	4.18	0.05	0.00	1647
2026-02-18	ADCT	4.12	0.04	0.00	1675
2026-02-20	ADCT	4.1	0.04	0.00	1697
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-01-23	ADCT	3.60	-	-	-1.41
2026-01-26	ADCT	3.62	-	-	-1.41
2026-01-27	ADCT	3.58	-	-	-1.41
2026-01-28	ADCT	3.55	-	-	-1.41
2026-01-29	ADCT	3.77	-	-	-1.41
2026-01-30	ADCT	3.63	-	-	-1.41
2026-02-02	ADCT	3.91	-	-	-1.41
2026-02-03	ADCT	3.91	-	-	-1.41
2026-02-04	ADCT	4.11	-	-	-1.41
2026-02-05	ADCT	3.92	-	-	-1.41
2026-02-06	ADCT	4.00	-	-	-1.41
2026-02-09	ADCT	3.99	-	-	-1.41
2026-02-10	ADCT	3.91	-	-	-1.41
2026-02-11	ADCT	3.91	-	-	-1.41
2026-02-12	ADCT	4.02	-	-	-1.41
2026-02-13	ADCT	4.01	-	-	-1.41
2026-02-17	ADCT	4.17	-	-	-1.41
2026-02-18	ADCT	4.14	-	-	-1.41
2026-02-19	ADCT	4.24	-	-	-1.41
2026-02-20	ADCT	4.11	-	-	-1.41
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-01-23	ADCT	0.00	1.76	3.51
2026-01-26	ADCT	0.00	1.76	3.51
2026-01-27	ADCT	0.00	1.76	3.51
2026-01-28	ADCT	0.00	1.76	3.76
2026-01-29	ADCT	0.00	1.76	3.76
2026-01-30	ADCT	0.00	1.76	3.76
2026-02-02	ADCT	0.00	1.86	3.76
2026-02-03	ADCT	0.00	1.86	3.76
2026-02-04	ADCT	0.00	1.86	3.76
2026-02-05	ADCT	0.00	1.86	3.76
2026-02-06	ADCT	0.00	1.86	3.76
2026-02-10	ADCT	0.00	2.79	3.76
2026-02-11	ADCT	0.00	2.79	4.34
2026-02-12	ADCT	0.00	2.79	4.34
2026-02-13	ADCT	0.00	2.79	4.34
2026-02-17	ADCT	0.00	3.72	4.34
2026-02-18	ADCT	0.00	3.72	4.34
2026-02-19	ADCT	0.00	3.72	4.34
2026-02-20	ADCT	0.00	3.72	4.34
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

-0.3

Avg. EPS Est. Current Quarter

-0.29

Avg. EPS Est. Next Quarter

-0.27

Insider Transactions

Institutional Transactions

3.72

Beta

1.91

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

87.2

Max Drawdown 5-Year %

-98.5

Target Price

P/E

Forward P/E

PEG

P/S

6.75

P/B

P/Free Cash Flow

EPS

-1.45

Average EPS Est. Cur. Y

-1.41

EPS Next Y. (Est.)

-1.08

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-221.97

Relative Volume

0.54

Return on Equity vs Sector %

41.1

Return on Equity vs Industry %

58.5

EPS 1 7Days Diff

EPS 1 30Days Diff

0.11

EBIT Estimation

ADC Therapeutics SA

Sector: Healthcare

Industry: Biotechnology

Employees: 263

ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound' and ADCT-602 that is in a Phase 1/2 IIT in refractory B-cell acute lymphoblastic leukemia. Further, the company's pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

stock quote shares ADCT – Adc Therapeutics SA Stock Price stock today

news today ADCT – Adc Therapeutics SA stock forecast ,stock prediction 2023 2024 2025

marketwatch ADCT – Adc Therapeutics SA yahoo finance google finance

stock history ADCT – Adc Therapeutics SA invest stock market

stock prices ADCT premarket after hours

ticker ADCT fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: ADCT

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y